Thursday, April 23, 2020

08:00–08:05 Welcome

SESSION I – Etiology of MDS
Chairs: Charlotte Niemeyer (Freiburg) & Austin Kulasekararaj (London)

08:05-08:20 Therapy related MDS and other environmental factors in MDS
08:20-08:25 Discussion

08:25-08:40 Genetic predisposition to MDS and acute leukemia
08:40-08:45 Discussion

08:45-09:00 CHIP / functional implications in MDS and AML
09:00-09:05 Discussion

09:05-09:20 Inflammation of HSCs as a potential driver of ineffective hematopoiesis
09:20-09:25 Discussion

09:25-09:40 Relationships between inherited and acquired predisposition
09:40-09:45 Discussion

09:45-09:52 Short communication
09:52-09:55 Discussion

09:55-10:02 Short communication
10:02-10:05 Discussion

10:05-10:35 Panel discussion

10:35-11:05 Coffee Break
SESSION II – Biology of MDS – Genetic Abnormalities
Chairs: Maria (Ken) Figueroa (Miami) & Mikkael Sekeres (Cleveland)

11:05-11:20 Review of currently available pre-clinical models (including zebra fish) of MDS
Daniel Nowak (Mannheim)
11:20-11:25 Discussion

11:25-11:40 Multiple acquired clonal steps to MDS, molecular architecture and its progression to AML
Olivier Kosmider (Paris)
11:40-11:45 Discussion

11:45-12:00 Druggable molecular targets in MDS and elderly AML (IDH, TP53...)
Torsten Haferlach (Munich)
12:00-12:05 Discussion

12:05-12:20 Epigenetic abnormalities in MDS and their relationship with somatic mutations
Maria (Ken) Figueroa (Miami)
12:20-12:25 Discussion

12:25-12:40 Spliceosome mutations and their consequences in MDS?
Austin Kulasekararaj (London)
12:40-12:45 Discussion

12:45-12:52 Short communication
Speaker
12:52-12:55 Discussion

12:55-13:15 Panel discussion

13:15-14:55 Lunch

13:45-14:45 Possible slot for a satellite symposium (No longer available)

SESSION III – Biology of MDS: Stem Cells and the Microenvironment
Chairs: Hind Medyouf (Frankfurt) & Uwe Platzbecker (Leipzig)

14:55-15:10 The niche in MDS: Inflammation driving evolution
Marc H.G.P. Raaijmakers (Rotterdam)
15:10-15:15 Discussion

15:15-15:30 Bone biology and the osteo-hematopoietic niche
Lorenz C. Hofbauer (Dresden)
15:30-15:35 Discussion

15:35-15:50 Hematopoietic stem cells in MDS: The real targets?
Ulrich Steidl (New York)
15:50-15:55 Discussion

15:55-16:10 Mesenchymal stem cells in MDS: The better targets?
Hind Medyouf (Frankfurt)
16:10-16:15 Discussion

16:15-16:30 Immunological mess in MDS; is there a target?
Shahram Kordasti (London)
16:30-16:35 Discussion
16:35-17:05  **Controversial debate**  
**Chairs: TBA**  
Genetics versus epigenetics in myeloid disease  
16:35-16:45  Genetics  Torsten Haferlach (Munich)  
16:45-16:55  Epigenetics  Maria (Ken) Figueroa (Miami)  
16:55-17:05  Discussion

17:05-17:35  **Coffee break**

**SESSION IV – Diagnostic Workup and Prognostic Factors in MDS**  
**Chairs: Ari Giagounidis (Düsseldorf) & Felicitas Thol (Hannover)**

17:35-17:50  Morphology (including WHO 2018 classification), cytogentics and flow cytometry  Ari Giagounidis (Düsseldorf)  
17:50-17:55  Discussion

17:55-18:10  Examining prognostic indicators in MDS  Heinz Tüchler (Vienna)  
18:10-18:15  Discussion

18:15-18:30  Role of comorbidities and quality of life in prognosis. New evaluation scales (QUALMS...)  Reinhard Stauder (Innsbruck)  
18:30-18:35  Discussion

18:35-19:05  Round table on Response criteria (with recent proposed changes, IWG 2018)  Uwe Platzbecker, Pierre Fenaux, Austin Kulasekararaj, Mikkael Sekkeres

19:05-19:35  **DEBATE: IS NGS useful in MDS?**  
No – Guillermo Sanz (Valencia)  
Yes – Felicitas Thol (Hannover)

19:40  Poster walks and stand up Get-Together buffet dinner for all)

**Friday, April 24, 2020**

**08:00-09:00** 3 Simultaneous Meet the Expert sessions (non-clinical)  
Flow cytometry in MDS  Arjan Van de Lossdrecht (Amsterdam)  
Technical aspects  Jaroslaw Maciejewski (Cleveland)  
Analysis of somatic mutations, of SNP etc.  Luca Malcovati (Pavia)

**08:00-09:00** Possible slot for a satellite symposium

**SESSION V – Specific Subtypes of MDS, based on Morphology and Molecular Biology**  
**Chairs: Michaela Fontenay (Paris) & Eric Solary (Villejuif)**  
09:00-09:15  MDS with Ring sideroblasts  Michaela Fontenay (Paris)  
09:15-09:20  Discussion
SESSION VI – Treatment of MDS
Chairs: Eva Hellström-Lindberg (Stockholm) & Raphael Itzykson (Paris)

11:20-11:35 Overview of MDS treatment  Eva Hellström-Lindberg (Stockholm)
11:35-11:40 Discussion

11:40-11:55 ESA and other growth factors  Valeria Santini (Firenze)
11:55-12:00 Discussion

12:00-12:15 HMAs: When and how  Mikkael Sekeres (Cleveland)
12:15-12:20 Discussion

12:20-12:35 Allo Transplantation: when and how?  Marie Robin (Paris)
12:35-12:40 Discussion

12:40-12:55 Current treatment guidelines for CMML and rare subtypes  Raphael Itzykson (Paris)
12:55-13:00 Discussion

13:00-13:07 Short communication  Speaker
13:07-13:10 Discussion

13:10-13:30 Panel discussion

13:30-15:10 Lunch

14:00-15:00 Possible slot for a satellite symposium (No longer available)

SESSION VII – Current Progress in the Treatment of MDS
Chairs: Valeria Santini (Firenze) & Lionel Adès (Paris)

A renewed role for intensive chemotherapy (CPX 351...)?
15:25-15:30 Discussion
15:30-15:45 Strategies to improve HMA based therapy  
15:45-15:50 Discussion  

15:50-16:20 Coffee break  

16:20-16:35 Management of HMA failure  
16:35-16:40 Discussion  

16:40-16:55 Novel strategies to treat cytopenia in Low Risk MDS  
16:55-17:00 Discussion  

17:00-17:07 Short communication  
17:07-17:10 Discussion  

17:10-17:30 Panel discussion  

### Saturday, April 25, 2020

#### SESSION VIII – Future Treatments and Treatment Strategies in MDS?  
**Chairs: Maria Diez Campelo (Salamanca) & Pierre Fenaux (Paris)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:45</td>
<td>Regulatory issues: registration of drugs in haematology</td>
<td>Axel Glasmacher (Bonn)</td>
</tr>
<tr>
<td>08:45-08:50</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>08:50-09:30</td>
<td>Current MDS/CMML clinical trials in Europe and North America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speakers: Valeria Santini (FISM), Maria Diaz Campelo (GESMD), Pierre Fenaux (GFM), Uwe Platzbecker (GMDS and EMSCO), M Sekeres (US MDS consortium)</td>
<td></td>
</tr>
<tr>
<td>09:30-09:35</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:35-09:50</td>
<td>How to target CHIP?</td>
<td>Klaus Metzeler (Munich)</td>
</tr>
<tr>
<td>09:50-09:55</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:55-10:02</td>
<td>Short communication</td>
<td>Speaker</td>
</tr>
<tr>
<td>10:02-10:05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:05-10:25</td>
<td>Panel discussion</td>
<td></td>
</tr>
</tbody>
</table>

10:25-10:55 Coffee break

### SESSION IX – “Late-Breaking” talks or a”Late-Breaking“ session

**Chairs: Maria Diez Campelo (Salamanca) & Pierre Fenaux (Paris)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55-11:10</td>
<td>Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>11:10-11:15</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
Draft: 24/02/2020

11:15-11:30  Title
11:30-11:35  Discussion

11:35-11:55 Closing Remarks

*Pending confirmation